Camptothecins in Cancer Therapy

  • Val R. Adams
  • Thomas G. Burke
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Biochemistry, Pharmacology, and Chemistry

    1. Front Matter
      Pages 1-1
    2. Leroy F. Liu, Shyamal D. Desai
      Pages 3-21
    3. Alex B. Burgin Jr., Michael D. Feese, Bart L. Staker, Lance Stewart
      Pages 23-38
    4. Sidney M. Hecht
      Pages 39-59
    5. Yves G. Pommier, Juana Barceló, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet, ZhiYong Liao
      Pages 61-107
    6. Robert C. A. M. van Waardenburg, Mary-Ann Bjornsti
      Pages 109-125
    7. Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, Peter J. Houghton
      Pages 127-151
    8. Zeshaan A. Rasheed, Eric H. Rubin
      Pages 153-169
    9. Thomas G. Burke, Tian-Xiang Xiang, Bradley D. Anderson, Lori J. Latus
      Pages 171-190
  3. Clinical Perspectives

    1. Front Matter
      Pages 191-191
    2. Chris H. Takimoto
      Pages 193-206
    3. Hilary Hewes, Judith A. Smith, Claire Verschraegen
      Pages 207-228
    4. Laurent P. Rivory
      Pages 229-262
    5. Aimee K. Bence, Val R. Adams
      Pages 263-299
    6. Keith T. Flaherty, James P. Stevenson, Christopher J. Twelves, Peter J. O’Dwyer
      Pages 301-316
    7. Clinton F. Stewart, Markos Leggas, Henry S. Friedman
      Pages 343-367
    8. Pankaj Kumar, Missak Haigentz Jr., Jorge Gomez, Roman Perez-Soler
      Pages 369-419
    9. Benjamin M. F. Mow, Scott H. Kaufmann
      Pages 421-450

About this book

Introduction

Clinical interest in the camptothecins continues to expand even though this class of topoisomerase I inhibitors has been studied for almost 50 years, and two early generation members of the family have gained FDA approval. In Camptothecins in Cancer Therapy, leading clinicians and researchers critically review our current understanding of camptothecins, their shortcomings, and the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.
Authoritative and up-to-date, Camptothecins in Cancer Therapy provides a comprehensive summary of camptothecin research, as well as a much-needed guide to all the latest information on their optimal therapeutic applications.

Keywords

DNA biochemistry brain brain tumors cancer cancer therapy chemistry drug drug delivery drug design leukemia pharmacology poison research resistance

Editors and affiliations

  • Val R. Adams
    • 1
  • Thomas G. Burke
    • 2
    • 3
    • 4
  1. 1.Department of Pharmacy Practice and Science, College of PharmacyUniversity of KentuckyLexington
  2. 2.Department of Pharmaceutical Sciences, College of PharmacyUniversity of KentuckyLexington
  3. 3.Experimental Therapeutics Program, Lucille P. Markey Cancer CenterUniversity of Kentucky Medical Center, University of KentuckyLexington
  4. 4.Tigen Pharmaceuticals Inc.Lexington

Bibliographic information

  • DOI https://doi.org/10.1385/1592598668
  • Copyright Information Humana Press Inc. 2005
  • Publisher Name Humana Press
  • eBook Packages Medicine
  • Print ISBN 978-1-58829-027-4
  • Online ISBN 978-1-59259-866-3
  • About this book